Skip to main content

Advertisement

Table 1 Characteristics and outcomes of confirmed pneumocystis jiroveci pneumonia in non-HIV patients

From: Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study

  Survivors Non-survivors P value
N = 20 N = 62
Age, mean ± SD 45 ± 17 55 ± 16 0.014
Male, n (%) 6(30.0) 28(45.2) 0.231
Apache II, mean ± SD 17 ± 5 20 ± 5 0.010
Underlying disease
 CTD, n (%) 16(80.0) 49(79.0) 0.926
  ILD, n (%) 1(5.0) 1(1.6) 0.431
  Dermatomyositis, n (%) 1(5.0) 9(14.5) 0.438
 Organ transplant, n (%) 2(10.0) 1(1.6) 0.146
 Hematologic malignancy, n (%) 0(0) 3(4.8) 0.427
 Solid tumor, n (%) 2(10.0) 2(3.2) 0.249
 Corticosteroid therapy, n (%) 17(94.4) 52(89.7) 0.539
Symptom
 Fever, n (%) 20(100) 50(80.6) 0.033
 Dyspnea, n (%) 19(95.0) 56(90.3) 0.515
 Cough, n (%) 15(75) 42(67.7) 0.540
Microbiological methods
 PCR, n (%) 17(85.0) 54(87.1) 0.811
 Methenamine silver stain, n (%) 11(55.0) 24(38.7) 0.200
Repiratory samples
 Sputum, n (%) 0(0) 6(9.7) 0.148
 Trachea aspirate, n (%) 6(30.0) 16(25.8) 0.713
 Bronchoalveolar lavage, n (%) 14(70.0) 40(64.5) 0.653
Laboratory findings
 White blood cell counts, mean ± SD 10.48 ± 4.62 7.68 ± 3.44 0.005
 lymphocyte counts, mean ± SD 678 ± 600 514 ± 441 0.117
 CD4 cell counts, mean ± SD 215 ± 225 159 ± 343 0.510
 PaO2/FiO2 on ICU admission 161 ± 69 131 ± 65 0.064
Radiographic findings
 Ground glass opacities, n (%) 20(100.0) 62(100.0)  
 Bilateral symmetric, n (%) 17(85.0) 55(88.7) 0.700
Co-infections
 Bacteremia, n (%) 2(10.0) 6(9.7) 0.966
 VAP, n (%) 5(25.0) 27(43.5) 0.139
 Aspergillosis, pulmonary, n (%) 5(25.0) 13(21.0) 0.705
 Cytomegalovirus, n (%) 10(50.0) 40(64.5) 0.247
Complications
 Hypotension, n (%) 4(20.0) 36(58.1) 0.003
  NE(mcg/kg/min), mean ± SD 0.22 ± 0.16 0.39 ± 0.36 0.439
 Barotrauma
  Pneumothorax, n (%) 2(10.0) 9(14.5) 0.465
  Pneumomediastinum, n (%) 1(5.0) 18(29) 0.027
Intervals
 Onset to diagnosis, days, mean ± SD 15 ± 12 14 ± 10 0.488
 Onset to intubation, days, mean ± SD 10 ± 6 12 ± 11 0.786
 Onset to TMP/SMZ, days, mean ± SD 14 ± 18 11 ± 10 0.538
Respiratory support
 IPPV during ICU stay, n (%) 16(80.0) 59(95.2) 0.057
 NPPV on ICU admission, n (%) 4(20.0) 8(12.9) 0.474
 IPPV on ICU admission, n (%) 10(50.0) 36(58.1) 0.527
 NRM on ICU admission, n (%) 6(30.0) 18(29.0) 0.934
Medication
 Adjunctive steroid, n (%) 16(80.0) 48(77.4) 0.808
 Caspofungin, n (%) 7(35.0) 31(50.0) 0.242
  1. Values are expressed as the mean ± SD or Number (%), unless otherwise indicated. CTD Connective Tissue Disease, ILD Interstitial lung Disease, PCR polymerase chain reaction, BALF bronchoalveolar lavage fluid, VAP ventilator-associated pneumonia, NE norepinephrine, TMP/SMZ trimethoprim-sulfamethoxazole, IPPV Invasive positive pressure ventilation, NPPV noninvasive positive pressure ventilation, NRM non-rebreathing mask